The efficacy and acceptability of the combination of acebutolol and hydrochlorothiazide in the treatment of essential hypertension.
The efficacy and acceptability of a single half-tablet daily of a fixed combination of 400 mg acebutolol and 25 mg hydrochlorothiazide was assessed in a study of 35 patients suffering from mild to moderate essential hypertension. The results of the 22 patients who completed the 3-month active drug period showed that treatment produced a significant reduction in supine systolic and diastolic blood pressure. This effect was apparent from the first week and was maintained throughout the trial. Pulse rate was also lowered by therapy. No clinically significant changes from normal were observed in mean serum potassium and uric acid levels, and no side-effects of treatment were reported.
D000070:Acebutolol / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011674:Pulse / Q000187:drug effects; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D004338:Drug Combinations; D006852:Hydrochlorothiazide; D014527:Uric Acid; D000070:Acebutolol; D011188:Potassium